Sunshine Historical Income Statement

SBFMW Stock

USD 0.17 0.04 19.05%

Historical analysis of Sunshine Biopharma income statement accounts such as Selling General Administrative of 10.6 M, Selling And Marketing Expenses of 771 K, Total Other Income Expense Net of 708.1 K or Research Development of 1.9 M can show how well Sunshine Biopharma Warrant performed in making a profits. Evaluating Sunshine Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Sunshine Biopharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Sunshine Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sunshine Biopharma is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

About Sunshine Income Statement Analysis

Sunshine Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Sunshine Biopharma shareholders. The income statement also shows Sunshine investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Sunshine Biopharma Income Statement Chart

At this time, Sunshine Biopharma's Gross Profit is fairly stable compared to the past year. Net Interest Income is likely to climb to about 632.4 K in 2024, whereas EBIT is likely to drop (4.2 M) in 2024.

Other Operating Expenses Total Operating Expenses Selling General Administrative Selling And Marketing Expenses Tax Provision

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Sunshine Biopharma. It is also known as Sunshine Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Sunshine Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Gross Profit is fairly stable compared to the past year. Net Interest Income is likely to climb to about 632.4 K in 2024, whereas EBIT is likely to drop (4.2 M) in 2024.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	2.7M	13.0M	28.9M	30.3M
Interest Expense	328.8K	39.4K	137.3K	148.9K

Other Operating Expenses Interest Expense

Sunshine Biopharma income statement Correlations

	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Selling General Administrative	Selling And Marketing Expenses	Total Other Income Expense Net	Research Development	Depreciation And Amortization	Total Revenue	Gross Profit	Discontinued Operations	Net Interest Income	Net Income From Continuing Ops	Cost Of Revenue	Reconciled Depreciation
Interest Expense		-0.08	0.17	0.08	0.08	-0.12	0.09	0.09	-0.09	-0.14	0.03	-0.28	0.01	0.01	-0.06	-0.06	-0.02	-0.18	0.07	-0.05	-0.06
Other Operating Expenses	-0.08		-0.71	-0.3	-0.29	0.97	-0.28	-0.31	-0.01	0.96	0.53	0.27	0.97	0.57	0.98	0.99	-0.52	0.95	-0.9	0.98	0.82
Operating Income	0.17	-0.71		0.85	0.85	-0.85	0.85	0.86	-0.02	-0.88	-0.41	-0.12	-0.7	-0.38	-0.57	-0.58	0.56	-0.81	0.91	-0.55	-0.3
Ebit	0.08	-0.3	0.85		1.0	-0.5	1.0	0.99	0.07	-0.54	-0.29	0.21	-0.34	-0.13	-0.12	-0.14	0.55	-0.43	0.67	-0.1	0.2
Ebitda	0.08	-0.29	0.85	1.0		-0.49	1.0	0.99	0.07	-0.53	-0.29	0.21	-0.34	-0.12	-0.11	-0.13	0.56	-0.43	0.66	-0.09	0.21
Total Operating Expenses	-0.12	0.97	-0.85	-0.5	-0.49		-0.49	-0.51	-0.01	1.0	0.53	0.24	0.95	0.55	0.91	0.92	-0.57	0.97	-0.97	0.91	0.71
Income Before Tax	0.09	-0.28	0.85	1.0	1.0	-0.49		1.0	0.01	-0.52	-0.32	0.23	-0.33	-0.14	-0.11	-0.13	0.54	-0.42	0.65	-0.09	0.2
Net Income	0.09	-0.31	0.86	0.99	0.99	-0.51	1.0		-0.04	-0.54	-0.31	0.22	-0.35	-0.13	-0.13	-0.15	0.53	-0.44	0.67	-0.11	0.17
Income Tax Expense	-0.09	-0.01	-0.02	0.07	0.07	-0.01	0.01	-0.04		0.0	-0.08	-0.02	-0.02	0.05	-0.01	-0.02	0.39	-0.02	0.04	0.0	0.18
Selling General Administrative	-0.14	0.96	-0.88	-0.54	-0.53	1.0	-0.52	-0.54	0.0		0.53	0.25	0.93	0.54	0.89	0.9	-0.56	0.97	-0.97	0.88	0.68
Selling And Marketing Expenses	0.03	0.53	-0.41	-0.29	-0.29	0.53	-0.32	-0.31	-0.08	0.53		-0.16	0.48	0.19	0.51	0.51	-0.62	0.48	-0.53	0.49	0.24
Total Other Income Expense Net	-0.28	0.27	-0.12	0.21	0.21	0.24	0.23	0.22	-0.02	0.25	-0.16		0.09	0.05	0.28	0.28	0.28	0.45	-0.07	0.29	0.45
Research Development	0.01	0.97	-0.7	-0.34	-0.34	0.95	-0.33	-0.35	-0.02	0.93	0.48	0.09		0.58	0.95	0.96	-0.56	0.88	-0.92	0.95	0.77
Depreciation And Amortization	0.01	0.57	-0.38	-0.13	-0.12	0.55	-0.14	-0.13	0.05	0.54	0.19	0.05	0.58		0.58	0.57	0.08	0.48	-0.52	0.58	0.67
Total Revenue	-0.06	0.98	-0.57	-0.12	-0.11	0.91	-0.11	-0.13	-0.01	0.89	0.51	0.28	0.95	0.58		1.0	-0.45	0.89	-0.82	1.0	0.88
Gross Profit	-0.06	0.99	-0.58	-0.14	-0.13	0.92	-0.13	-0.15	-0.02	0.9	0.51	0.28	0.96	0.57	1.0		-0.46	0.9	-0.83	1.0	0.88
Discontinued Operations	-0.02	-0.52	0.56	0.55	0.56	-0.57	0.54	0.53	0.39	-0.56	-0.62	0.28	-0.56	0.08	-0.45	-0.46		-0.5	0.65	-0.43	0.01
Net Interest Income	-0.18	0.95	-0.81	-0.43	-0.43	0.97	-0.42	-0.44	-0.02	0.97	0.48	0.45	0.88	0.48	0.89	0.9	-0.5		-0.91	0.89	0.72
Net Income From Continuing Ops	0.07	-0.9	0.91	0.67	0.66	-0.97	0.65	0.67	0.04	-0.97	-0.53	-0.07	-0.92	-0.52	-0.82	-0.83	0.65	-0.91		-0.81	-0.55
Cost Of Revenue	-0.05	0.98	-0.55	-0.1	-0.09	0.91	-0.09	-0.11	0.0	0.88	0.49	0.29	0.95	0.58	1.0	1.0	-0.43	0.89	-0.81		0.9
Reconciled Depreciation	-0.06	0.82	-0.3	0.2	0.21	0.71	0.2	0.17	0.18	0.68	0.24	0.45	0.77	0.67	0.88	0.88	0.01	0.72	-0.55	0.9

Click cells to compare fundamentals

Sunshine Biopharma Account Relationship Matchups

Sunshine Biopharma income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	115.9K	168.1K	328.8K	39.4K	137.3K	148.9K
Other Operating Expenses	662.8K	648.3K	2.7M	13.0M	28.9M	30.3M
Operating Income	(641.6K)	(576.9K)	(2.4M)	(8.7M)	(4.8M)	(4.5M)
Ebit	(641.6K)	(2.6M)	(12.1M)	(26.5M)	(4.0M)	(4.2M)
Ebitda	(942.6K)	(2.6M)	(12.1M)	(26.4M)	(3.8M)	(4.0M)
Total Operating Expenses	651.7K	622.4K	2.6M	10.4M	13.1M	13.8M
Income Before Tax	(1.1M)	(2.8M)	(12.4M)	(26.5M)	(4.1M)	(4.3M)
Net Income	(1.5M)	(897.7K)	(12.8M)	(26.7M)	(4.5M)	(4.7M)
Income Tax Expense	383.4K	(1.9M)	328.8K	233.3K	395.2K	207.0K
Selling General Administrative	622.7K	547.4K	1.9M	8.9M	10.1M	10.6M
Total Other Income Expense Net	(436.4K)	(2.2M)	(10.0M)	489.6K	674.4K	708.1K
Research Development	15.2K	60.9K	672.2K	811.9K	1.9M	1.9M
Depreciation And Amortization	(301.0K)	14.1K	12.7K	25.2K	149.1K	156.6K
Total Revenue	21.1K	71.4K	228.4K	4.3M	24.1M	25.3M
Gross Profit	10.1K	45.6K	110.6K	1.7M	8.3M	8.8M
Net Income Applicable To Common Shares	(2.2M)	(1.7M)	(2.8M)	(12.4M)	(11.2M)	(10.6M)
Net Interest Income	(115.9K)	(168.1K)	(328.8K)	479.2K	602.3K	632.4K
Net Income From Continuing Ops	(1.1M)	(2.8M)	(12.4M)	(26.7M)	(26.8M)	(25.4M)
Cost Of Revenue	11.1K	25.8K	117.8K	2.6M	15.8M	16.5M
Reconciled Depreciation	13.8K	14.1K	12.7K	25.2K	125.8K	132.1K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sunshine Historical Income Statement

About Sunshine Income Statement Analysis

Sunshine Biopharma Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Tax Provision

Sunshine Biopharma income statement Correlations

Sunshine Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sunshine Biopharma income statement Accounts

Also Currently Popular

Additional Tools for Sunshine Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebitda
Selling General Administrative	+ 1.0	Total Operating Expenses
Net Income	+ 1.0	Income Before Tax
Gross Profit	+ 1.0	Total Revenue

Net Income From Continuing Ops	- 0.97	Selling General Administrative
Net Income From Continuing Ops	- 0.97	Total Operating Expenses
Net Income From Continuing Ops	- 0.92	Research Development
Net Income From Continuing Ops	- 0.91	Net Interest Income
Net Income From Continuing Ops	- 0.9	Other Operating Expenses
Selling General Administrative	- 0.88	Operating Income